Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 142

1.

Treatment of advanced AIDS-associated Kaposi sarcoma in resource-limited settings: a three-arm, open-label, randomised, non-inferiority trial.

Krown SE, Moser CB, MacPhail P, Matining RM, Godfrey C, Caruso SR, Hosseinipour MC, Samaneka W, Nyirenda M, Busakhala NW, Okuku FM, Kosgei J, Hoagland B, Mwelase N, Oliver VO, Burger H, Mngqibisa R, Nokta M, Campbell TB, Borok MZ; A5263/AMC066 protocol team.

Lancet. 2020 Mar 5. pii: S0140-6736(19)33222-2. doi: 10.1016/S0140-6736(19)33222-2. [Epub ahead of print]

2.

Can gut microbiota of men who have sex with men influence HIV transmission?

Coleman SL, Neff CP, Li SX, Armstrong AJS, Schneider JM, Sen S, Fennimore B, Campbell TB, Lozupone CA, Palmer BE.

Gut Microbes. 2020 Feb 10:1-10. doi: 10.1080/19490976.2019.1700756. [Epub ahead of print]

PMID:
32036739
3.

Characteristics and current clinical practices of opioid treatment programs in the United States.

Jones CM, Byrd DJ, Clarke TJ, Campbell TB, Ohuoha C, McCance-Katz EF.

Drug Alcohol Depend. 2019 Dec 1;205:107616. doi: 10.1016/j.drugalcdep.2019.107616. Epub 2019 Oct 17.

PMID:
31678836
4.

Distal Sensory Peripheral Neuropathy in Human Immunodeficiency Virus Type 1-Positive Individuals Before and After Antiretroviral Therapy Initiation in Diverse Resource-Limited Settings.

Vecchio AC, Marra CM, Schouten J, Jiang H, Kumwenda J, Supparatpinyo K, Hakim J, Sacktor N, Campbell TB, Tripathy S, Kumarasamy N, La Rosa A, Santos B, Silva MT, Kanyama C, Firnhaber C, Hosseinipour MC, Mngqibisa R, Hall C, Cinque P, Robertson K.

Clin Infect Dis. 2019 Aug 12. pii: ciz745. doi: 10.1093/cid/ciz745. [Epub ahead of print]

PMID:
31630166
5.

Progressive brain atrophy in chronically infected and treated HIV+ individuals.

Nir TM, Jahanshad N, Ching CRK, Cohen RA, Harezlak J, Schifitto G, Lam HY, Hua X, Zhong J, Zhu T, Taylor MJ, Campbell TB, Daar ES, Singer EJ, Alger JR, Thompson PM, Navia BA; HIV Neuroimaging Consortium.

J Neurovirol. 2019 Jun;25(3):342-353. doi: 10.1007/s13365-019-00723-4. Epub 2019 Feb 14.

PMID:
30767174
6.

Upregulation of Chitinase 1 in Alveolar Macrophages of HIV-Infected Smokers.

Logue EC, Neff CP, Mack DG, Martin AK, Fiorillo S, Lavelle J, Vandivier RW, Campbell TB, Palmer BE, Fontenot AP.

J Immunol. 2019 Mar 1;202(5):1363-1372. doi: 10.4049/jimmunol.1801105. Epub 2019 Jan 21.

7.

Inflammation and micronutrient biomarkers predict clinical HIV treatment failure and incident active TB in HIV-infected adults: a case-control study.

Shivakoti R, Gupte N, Tripathy S, Poongulali S, Kanyama C, Berendes S, Cardoso SW, Santos BR, La Rosa A, Mwelase N, Pillay S, Samaneka W, Riviere C, Sugandhavesa P, Bollinger RC, Balagopal A, Semba RD, Christian P, Campbell TB, Gupta A; NWCS 319 and PEARLS Study Team.

BMC Med. 2018 Sep 24;16(1):161. doi: 10.1186/s12916-018-1150-3.

8.

Human Immunodeficiency Virus-associated Neurocognitive Impairment in Diverse Resource-limited Settings.

Robertson KR, Jiang H, Kumwenda J, Supparatpinyo K, Marra CM, Berzins B, Hakim J, Sacktor N, Campbell TB, Schouten J, Mollan K, Tripathy S, Kumarasamy N, La Rosa A, Santos B, Silva MT, Kanyama C, Firhnhaber C, Murphy R, Hall C, Marcus C, Naini L, Masih R, Hosseinipour MC, Mngqibisa R, Badal-Faesen S, Yosief S, Vecchio A, Nair A; AIDS Clinical Trials Group.

Clin Infect Dis. 2019 May 2;68(10):1733-1738. doi: 10.1093/cid/ciy767.

9.

Human Immunodeficiency Virus Type 1 and Tuberculosis Coinfection in Multinational, Resource-limited Settings: Increased Neurological Dysfunction.

Robertson KR, Oladeji B, Jiang H, Kumwenda J, Supparatpinyo K, Campbell TB, Hakim J, Tripathy S, Hosseinipour MC, Marra CM, Kumarasamy N, Evans S, Vecchio A, La Rosa A, Santos B, Silva MT, Montano S, Kanyama C, Firnhaber C, Price R, Marcus C, Berzins B, Masih R, Lalloo U, Sanne I, Yosief S, Walawander A, Nair A, Sacktor N, Hall C; 5199 Study Team; and the AIDS Clinical Trials Group.

Clin Infect Dis. 2019 May 2;68(10):1739-1746. doi: 10.1093/cid/ciy718.

10.

Physical function improvements with moderate or high-intensity exercise among older adults with or without HIV infection.

Erlandson KM, MaWhinney S, Wilson M, Gross L, McCandless SA, Campbell TB, Kohrt WM, Schwartz R, Brown TT, Jankowski CM.

AIDS. 2018 Oct 23;32(16):2317-2326. doi: 10.1097/QAD.0000000000001984.

11.

Pregnancy outcomes among HIV-infected women who conceived on antiretroviral therapy.

Stringer EM, Kendall MA, Lockman S, Campbell TB, Nielsen-Saines K, Sawe F, Cu-Uvin S, Wu X, Currier JS.

PLoS One. 2018 Jul 18;13(7):e0199555. doi: 10.1371/journal.pone.0199555. eCollection 2018.

12.

Effect of baseline micronutrient and inflammation status on CD4 recovery post-cART initiation in the multinational PEARLS trial.

Shivakoti R, Ewald ER, Gupte N, Yang WT, Kanyama C, Cardoso SW, Santos B, Supparatpinyo K, Badal-Faesen S, Lama JR, Lalloo U, Zulu F, Pawar JS, Riviere C, Kumarasamy N, Hakim J, Pollard R, Detrick B, Balagopal A, Asmuth DM, Semba RD, Campbell TB, Golub J, Gupta A; NWCS 319 and ACTG PEARLS Study Team.

Clin Nutr. 2019 Jun;38(3):1303-1309. doi: 10.1016/j.clnu.2018.05.014. Epub 2018 May 29.

PMID:
29885777
13.

Fecal Microbiota Composition Drives Immune Activation in HIV-infected Individuals.

Neff CP, Krueger O, Xiong K, Arif S, Nusbacher N, Schneider JM, Cunningham AW, Armstrong A, Li S, McCarter MD, Campbell TB, Lozupone CA, Palmer BE.

EBioMedicine. 2018 Apr;30:192-202. doi: 10.1016/j.ebiom.2018.03.024. Epub 2018 Mar 26.

14.

Medical Education Partnership Initiative (MEPI) in Zimbabwe: Outcomes and Challenges.

Hakim JG, Chidzonga MM, Borok MZ, Nathoo KJ, Matenga J, Havranek E, Cowan F, Abas M, Aagaard E, Connors S, Nkomani S, Ndhlovu CE, Matsika A, Barry M, Campbell TB.

Glob Health Sci Pract. 2018 Mar 30;6(1):82-92. doi: 10.9745/GHSP-D-17-00052. Print 2018 Mar 21.

15.

As-Needed Vs Immediate Etoposide Chemotherapy in Combination With Antiretroviral Therapy for Mild-to-Moderate AIDS-Associated Kaposi Sarcoma in Resource-Limited Settings: A5264/AMC-067 Randomized Clinical Trial.

Hosseinipour MC, Kang M, Krown SE, Bukuru A, Umbleja T, Martin JN, Orem J, Godfrey C, Hoagland B, Mwelase N, Langat D, Nyirenda M, MacRae J, Borok M, Samaneka W, Moses A, Mngqbisa R, Busakhala N, MartĂ­nez-Maza O, Ambinder R, Dittmer DP, Nokta M, Campbell TB; A5264/AMC-067 REACT-KS Team.

Clin Infect Dis. 2018 Jul 2;67(2):251-260. doi: 10.1093/cid/ciy044.

16.

The Impact of Statin and Angiotensin-Converting Enzyme Inhibitor/Angiotensin Receptor Blocker Therapy on Cognitive Function in Adults With Human Immunodeficiency Virus Infection.

Erlandson KM, Kitch D, Wester CW, Kalayjian RC, Overton ET, Castillo-Mancilla J, Koletar SL, Benson CA, Campbell TB, Robertson K, Lok JJ.

Clin Infect Dis. 2017 Nov 29;65(12):2042-2049. doi: 10.1093/cid/cix645.

17.

Race/Ethnicity and the Pharmacogenetics of Reported Suicidality With Efavirenz Among Clinical Trials Participants.

Mollan KR, Tierney C, Hellwege JN, Eron JJ, Hudgens MG, Gulick RM, Haubrich R, Sax PE, Campbell TB, Daar ES, Robertson KR, Ventura D, Ma Q, Edwards DRV, Haas DW; AIDS Clinical Trials Group.

J Infect Dis. 2017 Sep 1;216(5):554-564. doi: 10.1093/infdis/jix248.

18.

Herpes Simplex Virus Type 2 Acquisition Among HIV-1-Infected Adults Treated With Tenofovir Disoproxyl Fumarate as Part of Combination Antiretroviral Therapy: Results From the ACTG A5175 PEARLS Study.

Celum C, Hong T, Cent A, Donnell D, Morrow R, Baeten JM, Firnhaber C, Grinsztejn B, Hosseinipour MC, Lalloo U, Nyirenda M, Riviere C, Sanchez J, Santos B, Supparatpinyo K, Hakim J, Kumarasamy N, Campbell TB; ACTG PEARLS/A5175 Team.

J Infect Dis. 2017 Mar 15;215(6):907-910. doi: 10.1093/infdis/jix029.

19.

Insulin-Like Growth Factor Is Associated with Changes in Body Composition with Antiretroviral Therapy Initiation.

Erlandson KM, Fiorillo SP, Cardoso SW, Riviere C, Sanchez J, Hakim J, Kumarasamy N, Badal-Faesen S, Lalloo U, Kumwenda J, Campbell TB, Brown TT.

AIDS Res Hum Retroviruses. 2017 Sep;33(9):929-934. doi: 10.1089/AID.2016.0327. Epub 2017 May 16.

20.

Vitamin A and D Deficiencies Associated With Incident Tuberculosis in HIV-Infected Patients Initiating Antiretroviral Therapy in Multinational Case-Cohort Study.

Tenforde MW, Yadav A, Dowdy DW, Gupte N, Shivakoti R, Yang WT, Mwelase N, Kanyama C, Pillay S, Samaneka W, Santos B, Poongulali S, Tripathy S, Riviere C, Berendes S, Lama JR, Cardoso SW, Sugandhavesa P, Christian P, Semba RD, Campbell TB, Gupta A; NWCS319 and ACTG 5175 study team.

J Acquir Immune Defic Syndr. 2017 Jul 1;75(3):e71-e79. doi: 10.1097/QAI.0000000000001308.

21.

Medical Education Partnership Initiative in Zimbabwe: partnerships for transformation.

Hakim JG, Barry M, Matenga J, Cowan F, Campbell TB.

Lancet Glob Health. 2017 Feb;5(2):e143-e144. doi: 10.1016/S2214-109X(17)30005-0. No abstract available.

22.

Rapid Multiplexed Immunoassay for Detection of Antibodies to Kaposi's Sarcoma-Associated Herpesvirus.

Logan C, Todorof K, Fiorillo SP, Campbell TB, Elder JH, Borok M, Gudza I, Gwanzura L, Ndemera B, Lochhead MJ, Benson CA, Schooley RT.

PLoS One. 2016 Sep 26;11(9):e0163616. doi: 10.1371/journal.pone.0163616. eCollection 2016.

23.

Predictors of late virologic failure after initial successful suppression of HIV replication on efavirenz-based antiretroviral therapy.

Singini I, Campbell TB, Smeaton LM, Kumarasamy N, La Rosa A, Taejareonkul S, Safren SA, Flanigan TP, Hakim JG, Hughes MD; ACTG A5175/PEARLS Study Team.

HIV Clin Trials. 2016;17(5):173-180. Epub 2016 Jul 29.

24.

Sex-Related Differences in Inflammatory and Immune Activation Markers Before and After Combined Antiretroviral Therapy Initiation.

Mathad JS, Gupte N, Balagopal A, Asmuth D, Hakim J, Santos B, Riviere C, Hosseinipour M, Sugandhavesa P, Infante R, Pillay S, Cardoso SW, Mwelase N, Pawar J, Berendes S, Kumarasamy N, Andrade BB, Campbell TB, Currier JS, Cohn SE, Gupta A; New Work Concept Sheet 319 and AIDS Clinical Trials Group A5175 (PEARLS) Study Teams.

J Acquir Immune Defic Syndr. 2016 Oct 1;73(2):123-9. doi: 10.1097/QAI.0000000000001095.

25.

Inflammation and Change in Body Weight With Antiretroviral Therapy Initiation in a Multinational Cohort of HIV-Infected Adults.

Mave V, Erlandson KM, Gupte N, Balagopal A, Asmuth DM, Campbell TB, Smeaton L, Kumarasamy N, Hakim J, Santos B, Riviere C, Hosseinipour MC, Sugandhavesa P, Infante R, Pillay S, Cardoso SW, Tripathy S, Mwelase N, Berendes S, Andrade BB, Thomas DL, Bollinger RC, Gupta A; ACTG PEARLS and NWCS 319 Study Team.

J Infect Dis. 2016 Jul 1;214(1):65-72. doi: 10.1093/infdis/jiw096. Epub 2016 Mar 8.

26.

Modulation of Hematopoietic Chemokine Effects In Vitro and In Vivo by DPP-4/CD26.

Broxmeyer HE, Capitano M, Campbell TB, Hangoc G, Cooper S.

Stem Cells Dev. 2016 Apr 15;25(8):575-85. doi: 10.1089/scd.2016.0026. Epub 2016 Mar 30.

27.

Pharmacogenetics of unboosted atazanavir in HIV-infected individuals in resource-limited settings: a sub-study of the AIDS Clinical Trials Group (ACTG) PEARLS study (NWCS 342).

Castillo-Mancilla JR, Aquilante CL, Wempe MF, Smeaton LM, Firnhaber C, LaRosa AM, Kumarasamy N, Andrade A, Baheti G, Fletcher CV, Campbell TB, Haas DW, MaWhinney S, Anderson PL.

J Antimicrob Chemother. 2016 Jun;71(6):1609-18. doi: 10.1093/jac/dkw005. Epub 2016 Feb 17.

28.

International neurocognitive normative study: neurocognitive comparison data in diverse resource-limited settings: AIDS Clinical Trials Group A5271.

Robertson K, Jiang H, Evans SR, Marra CM, Berzins B, Hakim J, Sacktor N, Silva MT, Campbell TB, Nair A, Schouten J; 5271 study team, Kumwenda J, Supparatpinyo K, Tripathy S, Kumarasamy N, la Rosa A, Montano S, Mwafongo A, Firnhaber C, Sanne I, Naini L, Amod F, Walawander A; AIDS Clinical Trials Group.

J Neurovirol. 2016 Aug;22(4):472-8. doi: 10.1007/s13365-015-0415-2. Epub 2016 Jan 5.

29.

Barriers to Accessing Emergency Medical Services in Accra, Ghana: Development of a Survey Instrument and Initial Application in Ghana.

Mould-Millman NK, Rominski SD, Bogus J, Ginde AA, Zakariah AN, Boatemaah CA, Yancey AH, Akoriyea SK, Campbell TB.

Glob Health Sci Pract. 2015 Dec 17;3(4):577-90. doi: 10.9745/GHSP-D-15-00170. Print 2015 Dec.

30.

Persistently Elevated C-Reactive Protein Level in the First Year of Antiretroviral Therapy, Despite Virologic Suppression, Is Associated With HIV Disease Progression in Resource-Constrained Settings.

Shivakoti R, Yang WT, Berendes S, Mwelase N, Kanyama C, Pillay S, Samaneka W, Santos B, Poongulali S, Tripathy S, Riviere C, Lama JR, Cardoso SW, Sugandhavesa P, Balagopal A, Gupte N, Semba RD, Campbell TB, Bollinger RC, Gupta A; NWCS 319 and PEARLS Study Team.

J Infect Dis. 2016 Apr 1;213(7):1074-8. doi: 10.1093/infdis/jiv573. Epub 2015 Nov 29.

31.

Multicenter Comparison of Lung and Oral Microbiomes of HIV-infected and HIV-uninfected Individuals.

Beck JM, Schloss PD, Venkataraman A, Twigg H 3rd, Jablonski KA, Bushman FD, Campbell TB, Charlson ES, Collman RG, Crothers K, Curtis JL, Drews KL, Flores SC, Fontenot AP, Foulkes MA, Frank I, Ghedin E, Huang L, Lynch SV, Morris A, Palmer BE, Schmidt TM, Sodergren E, Weinstock GM, Young VB; Lung HIV Microbiome Project.

Am J Respir Crit Care Med. 2015 Dec 1;192(11):1335-44. doi: 10.1164/rccm.201501-0128OC.

32.

A Randomized Comparison of Anthropomorphic Changes With Preferred and Alternative Efavirenz-Based Antiretroviral Regimens in Diverse Multinational Settings.

Erlandson KM, Taejaroenkul S, Smeaton L, Gupta A, Singini IL, Lama JR, Mngqibisa R, Firnhaber C, Cardoso SW, Kanyama C, Machado da Silva AL, Hakim JG, Kumarasamy N, Campbell TB, Hughes MD.

Open Forum Infect Dis. 2015 Jun 24;2(3):ofv095. doi: 10.1093/ofid/ofv095. eCollection 2015 Sep.

33.

Physical function impairment of older, HIV-infected adults is associated with cytomegalovirus immunoglobulin response.

Erlandson KM, Allshouse AA, Rapaport E, Palmer BE, Wilson CC, Weinberg A, MaWhinney S, Campbell TB.

AIDS Res Hum Retroviruses. 2015 Sep;31(9):905-12. doi: 10.1089/AID.2015.0085. Epub 2015 Jul 8.

34.

Presence of Plasmodium falciparum DNA in Plasma Does Not Predict Clinical Malaria in an HIV-1 Infected Population.

Orlov M, Smeaton LM, Kumwenda J, Hosseinipour MC, Campbell TB, Schooley RT.

PLoS One. 2015 Jun 8;10(6):e0129519. doi: 10.1371/journal.pone.0129519. eCollection 2015.

35.

Epidemiology of Kaposi's sarcoma-associated herpesvirus in HIV-1-infected US persons in the era of combination antiretroviral therapy.

Labo N, Miley W, Benson CA, Campbell TB, Whitby D.

AIDS. 2015 Jun 19;29(10):1217-25. doi: 10.1097/QAD.0000000000000682.

36.

Comparison of HBV-active HAART regimens in an HIV-HBV multinational cohort: outcomes through 144 weeks.

Thio CL, Smeaton L, Hollabaugh K, Saulynas M, Hwang H, Saravanan S, Kulkarni S, Hakim J, Nyirenda M, Iqbal HS, Lalloo UG, Campbell TB, Lockman S, Currier JS.

AIDS. 2015 Jun 19;29(10):1173-82. doi: 10.1097/QAD.0000000000000686.

37.

Pre-cART Elevation of CRP and CD4+ T-Cell Immune Activation Associated With HIV Clinical Progression in a Multinational Case-Cohort Study.

Balagopal A, Asmuth DM, Yang WT, Campbell TB, Gupte N, Smeaton L, Kanyama C, Grinsztejn B, Santos B, Supparatpinyo K, Badal-Faesen S, Lama JR, Lalloo UG, Zulu F, Pawar JS, Riviere C, Kumarasamy N, Hakim J, Li XD, Pollard RB, Semba RD, Thomas DL, Bollinger RC, Gupta A; ACTG PEARLS and NWCS 319 Study team.

J Acquir Immune Defic Syndr. 2015 Oct 1;70(2):163-71. doi: 10.1097/QAI.0000000000000696.

38.

Differences in antiretroviral safety and efficacy by sex in a multinational randomized clinical trial.

Firnhaber C, Smeaton LM, Grinsztejn B, Lalloo U, Faesen S, Samaneka W, Infante R, Rana A, Kumarasamy N, Hakim J, Campbell TB.

HIV Clin Trials. 2015 May-Jun;16(3):89-99. doi: 10.1179/1528433614Z.0000000013. Epub 2015 May 15.

39.

Plasma Sclerostin in HIV-Infected Adults on Effective Antiretroviral Therapy.

Erlandson KM, O'Riordan M, Hileman CO, Rapaport E, Labbato D, Campbell TB, McComsey GA.

AIDS Res Hum Retroviruses. 2015 Jul;31(7):731-8. doi: 10.1089/AID.2015.0052. Epub 2015 May 27.

40.

Concurrent Anemia and Elevated C-Reactive Protein Predicts HIV Clinical Treatment Failure, Including Tuberculosis, After Antiretroviral Therapy Initiation.

Shivakoti R, Yang WT, Gupte N, Berendes S, Rosa AL, Cardoso SW, Mwelase N, Kanyama C, Pillay S, Samaneka W, Riviere C, Sugandhavesa P, Santos B, Poongulali S, Tripathy S, Bollinger RC, Currier JS, Tang AM, Semba RD, Christian P, Campbell TB, Gupta A; New Work Concept Sheet 319 and The Prospective Evaluation of Antiretrovirals in Resource-Limited Settings Study Team.

Clin Infect Dis. 2015 Jul 1;61(1):102-10. doi: 10.1093/cid/civ265. Epub 2015 Mar 31.

41.

Normal and leukemic stem cell niches: insights and therapeutic opportunities.

Schepers K, Campbell TB, Passegué E.

Cell Stem Cell. 2015 Mar 5;16(3):254-67. doi: 10.1016/j.stem.2015.02.014. Review.

42.

C-reactive protein (CRP), interferon gamma-inducible protein 10 (IP-10), and lipopolysaccharide (LPS) are associated with risk of tuberculosis after initiation of antiretroviral therapy in resource-limited settings.

Tenforde MW, Gupte N, Dowdy DW, Asmuth DM, Balagopal A, Pollard RB, Sugandhavesa P, Lama JR, Pillay S, Cardoso SW, Pawar J, Santos B, Riviere C, Mwelase N, Kanyama C, Kumwenda J, Hakim JG, Kumarasamy N, Bollinger R, Semba RD, Campbell TB, Gupta A; ACTG PEARLS and NWCS 319 Study Group.

PLoS One. 2015 Feb 26;10(2):e0117424. doi: 10.1371/journal.pone.0117424. eCollection 2015.

43.

Prevalence and risk factors of micronutrient deficiencies pre- and post-antiretroviral therapy (ART) among a diverse multicountry cohort of HIV-infected adults.

Shivakoti R, Christian P, Yang WT, Gupte N, Mwelase N, Kanyama C, Pillay S, Samaneka W, Santos B, Poongulali S, Tripathy S, Riviere C, Berendes S, Lama JR, Cardoso SW, Sugandhavesa P, Tang AM, Semba RD, Campbell TB, Gupta A; NWCS 319 and PEARLS Study Team.

Clin Nutr. 2016 Feb;35(1):183-189. doi: 10.1016/j.clnu.2015.02.002. Epub 2015 Feb 10.

44.

Pretreatment HIV Drug Resistance and HIV-1 Subtype C Are Independently Associated With Virologic Failure: Results From the Multinational PEARLS (ACTG A5175) Clinical Trial.

Kantor R, Smeaton L, Vardhanabhuti S, Hudelson SE, Wallis CL, Tripathy S, Morgado MG, Saravanan S, Balakrishnan P, Reitsma M, Hart S, Mellors JW, Halvas E, Grinsztejn B, Hosseinipour MC, Kumwenda J, La Rosa A, Lalloo UG, Lama JR, Rassool M, Santos BR, Supparatpinyo K, Hakim J, Flanigan T, Kumarasamy N, Campbell TB, Eshleman SH; AIDS Clinical Trials Group (ACTG) A5175 Study Team.

Clin Infect Dis. 2015 May 15;60(10):1541-9. doi: 10.1093/cid/civ102. Epub 2015 Feb 13.

45.

The Impact of Marijuana Use on the Successful Aging of HIV-Infected Adults.

Allshouse AA, MaWhinney S, Jankowski CM, Kohrt WM, Campbell TB, Erlandson KM.

J Acquir Immune Defic Syndr. 2015 Jun 1;69(2):187-92. doi: 10.1097/QAI.0000000000000562.

46.

Plasma and Cerebrospinal Fluid Biomarkers Predict Cerebral Injury in HIV-Infected Individuals on Stable Combination Antiretroviral Therapy.

Anderson AM, Harezlak J, Bharti A, Mi D, Taylor MJ, Daar ES, Schifitto G, Zhong J, Alger JR, Brown MS, Singer EJ, Campbell TB, McMahon DD, Buchthal S, Cohen R, Yiannoutsos C, Letendre SL, Navia BA; HIV Neuroimaging Consortium.

J Acquir Immune Defic Syndr. 2015 May 1;69(1):29-35. doi: 10.1097/QAI.0000000000000532.

47.

Inflammation in Chronic HIV Infection: What Can We Do?

Erlandson KM, Campbell TB.

J Infect Dis. 2015 Aug 1;212(3):339-42. doi: 10.1093/infdis/jiv007. Epub 2015 Jan 12. No abstract available.

PMID:
25583171
48.

Lymphocytic alveolitis is associated with the accumulation of functionally impaired HIV-specific T cells in the lung of antiretroviral therapy-naive subjects.

Neff CP, Chain JL, MaWhinney S, Martin AK, Linderman DJ, Flores SC, Campbell TB, Palmer BE, Fontenot AP.

Am J Respir Crit Care Med. 2015 Feb 15;191(4):464-73. doi: 10.1164/rccm.201408-1521OC.

49.

Renal and metabolic toxicities following initiation of HIV-1 treatment regimen in a diverse, multinational setting: a focused safety analysis of ACTG PEARLS (A5175).

Touzard Romo F, Smeaton LM, Campbell TB, Riviere C, Mngqibisa R, Nyirenda M, Supparatpinyo K, Kumarasamy N, Hakim JG, Flanigan TP.

HIV Clin Trials. 2014 Nov-Dec;15(6):246-60. doi: 10.1310/hct1506-246.

50.

Pre-antiretroviral therapy serum selenium concentrations predict WHO stages 3, 4 or death but not virologic failure post-antiretroviral therapy.

Shivakoti R, Gupte N, Yang WT, Mwelase N, Kanyama C, Tang AM, Pillay S, Samaneka W, Riviere C, Berendes S, Lama JR, Cardoso SW, Sugandhavesa P, Semba RD, Christian P, Campbell TB, Gupta A; NWCS 319 and PEARLS study team.

Nutrients. 2014 Nov 13;6(11):5061-78. doi: 10.3390/nu6115061.

Supplemental Content

Loading ...
Support Center